Trial Profile
A retrospective database analysis comparing readmission rates among patients hospitalized for chronic obstructive pulmonary disease (COPD) who were treated with nebulized arformoterol tartrate compared to inhaled tiotropium
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Arformoterol (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 21 Oct 2015 New trial record
- 19 Oct 2015 According to a Sunovion media release, results from this trial will be presented at the 2015 American College of Chest Physicians annual meeting (CHEST).